Skip to main content
. 2024 Jan 17;12(1):101214. doi: 10.1016/j.gendis.2024.101214

Figure 6.

Figure 6

The IGF2BP1 inhibitor BTYNB effectively down-regulates CDC5L expression and suppresses the proliferation of MM cells in vivo. (A–C) The level of CDC5L protein decreased gradually with the duration of BTY treatment in NCI-H929, RPMI-RPMI-RPMI-8226, and MM1.S cells. (D) BTYNB dose-dependently decreased the cell viability of NCI-H929, RPMI-RPMI-RPMI-8226, and MM1.S cells, as revealed by CCK-8 assays of the indicated cells after treatment with BTYNB at the concentrations from 0 to 30 μM for 48 h. (E) Flow cytometry analysis was subsequently performed to assess the apoptosis rate of NCI-H929 and RMPI-8226 cells after 48-h exposure to the IGF2BP1 inhibitor BTYNB. The percentage of apoptotic cells, encompassing both early and late apoptosis, exhibited a noteworthy increase with escalating concentrations of BTYNB. (F) The B-NDG mice inoculated with NCI-H929 cells were treated with BTYNB or placebo. The images of tumors on day 23 are shown. IGF2BP1, insulin-like growth factor 2 mRNA binding protein 1; CDC5L, cell division cycle 5-like; MM, multiple myeloma.